Delfi Diagnostics reported that its cell-free DNA liquid biopsy test, FirstLook Lung, increased lung cancer screening uptake by nearly threefold in a cluster-randomized interventional FIRSTLUNG trial presented at the American Thoracic Society International Conference. The trial enrolled nearly 3,000 patients who were behind on recommended screening across 28 clinics in Colorado, Florida and North Carolina. Delfi said the assay showed 80% sensitivity, 56% specificity and a 99.8% negative predictive value. The company also reported a 1.5-fold increase in low-dose CT (LDCT) screening tied to test access. In addition, Delfi highlighted follow-up behavior after positive results: 42% of patients receiving a positive FirstLook Lung result proceeded to LDCT. The company also emphasized that many detected cancers were stage I, aiming to support curative-intent treatment access. If results are confirmed in peer-reviewed publication, cfDNA screening add-ons like FirstLook Lung could shift how providers reach under-screened populations while maintaining adherence to existing guideline pathways.